We have a strong history of delivering biological medicines for immunological diseases and we continue to build a pipeline of exciting, new biotechnological products, while expanding into small-molecule oral medications and broadening our disease focus in autoimmune, inflammatory and pulmonary diseases. Through our ongoing efforts in discovery, biomarkers, clinical research and external innovation, we are poised for continued leadership and growth, bringing transformational medicines to patients and healthcare providers around the world.
Read our Janssen in immunology leaflet to learn more about our commitment to immunology.
A Psoriasis White Paper, which addresses the under-treatment of psoriasis in Europe and provides a framework for action, has been published in the Journal of the European Academy of Dermatology and Venereology (JEADV). Authored by the European Expert Working Group for Healthcare in Psoriasis (EEWGHP) and financially supported by Janssen, this Psoriasis White Paper entitled ‘A framework for improving the quality of care for people with psoriasis’ is a key milestone for treatment in the disease area.